Top 10 AI-Powered Biotech Stocks to Buy Now

7. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Number Of Hedge Fund Holders: 27

Relay Therapeutics, Inc. (NASDAQ:RLAY) is advancing its position in AI-powered oncology with a focus on targeting protein dynamics through computational modeling, structural biology, and molecular simulations. Its proprietary platform is designed to create small-molecule drugs that address complex cancer pathways once considered untreatable.

Relay Therapeutics, Inc. (NASDAQ:RLAY) ’s lead candidate, RLY-2608, a PIK3CA inhibitor, is in late-stage trials for breast cancer and has emerged as a major driver of momentum this month. Recent data show strong efficacy and a clean safety profile, drawing significant analyst attention and positioning the therapy as a front-runner in precision oncology. Beyond breast cancer, RLY-2608 is also being evaluated for vascular malformations, opening potential pathways into rare pediatric indications. This progress has sparked optimism, with analysts assigning a buy rating and projecting a price target nearly four times current levels.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is further strengthening its pipeline through collaborations with Pfizer and Elevar Therapeutics, partnerships that are expected to accelerate commercialization and broaden clinical adoption. Alongside RLY-2608, the corporation is expanding its portfolio of small-molecule inhibitors to tackle hard-to-treat cancers, supported by its integration of high-performance computing, experimental validation, and strategic alliances.